CompoAtlas

Rinorub Bronches N-acétylcystéine

Food supplement declared in France, declaration No 2024-2-1217, decision dated 20 February 2024

Rinorub Bronches N-acétylcystéine (Forté Pharma) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Echinacea angustifolia 162.8 mg per day, Eucalyptus globulus 45.3 mg per day, Hedera helix 31 mg per day, Copper, Acétylcystéine. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Forté Pharma
Food business operator placing the product on the market
Laboratoire FORTE PHARMA SA
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Bottle
Daily dose
40 ml
Directions for use
Prendre 20 ml deux fois par jour, de préférence le matin et à midi.
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Pregnant women, Ulcer (stomach or duodenum), Prolonged use
Objectives stated by the manufacturer (these are not authorised claims)
Respiratory tract, Immunity
Flavourings
eucalytus

Declaration 139302, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Echinacea angustifolia DC.RacineExtrait sec hydroalcoolique162.8 mg
Eucalyptus globulus Labill.Essence (feuille)Distillation45.3 mg
Hedera helix L.FeuilleExtrait sec hydroalcoolique31 mg

Other active ingredients

NamePer day
Acétylcystéinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
cupric gluconateCopper5,000 µg2,000 µg

Additives

E415, E202, E211, E950, E955

Other ingredients

eau

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne pas utiliser chez la femme enceinte ou qui allaite, les personnes âgées et chez les enfants de moins de 12 ans. Ne pas utiliser de manière prolongée sans avis médical.Déconseillé aux personnes asthmatiques, épileptiques, aux personnes souffrant d’hypertension ou ayant des antécédents de convulsion sans l’avis d’un professionnel de santé. Ne pas dépasser un mois de prise. Déconseillé en cas d’ulcère ou d’inflammation du tractus digestif. Déconseillé en cas d’allergie connue à l’Eucalyptus ou au 1,8-cinéole. Déconseillé en cas de pathologie du système immunitaire ou de prise de médicaments affectant le système immunitaire.Déconseillé en cas d'allergie croisée connue, en particulier aux plantes de la famille des Asteraceae et des Araliaceae.Ce complément alimentaire n’est pas un médicament. Ne pas utiliser en cas d’hypersensibilité à l’échinacée.Informez votre médecin ou pharmacien en cas de prise simultanée de médicaments.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Echinacea angustifolia DC.
    Read the warning, when it applies and the studies cited

    ECHINACEA- ECHINACEA ANGUSTIFOLIA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a progressive systemic disease such as tuberculosis, collagenosis, multiple sclerosis, or an immune system disorder (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications to suppress the immune system (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 28 March 2025

  • Acétylcystéine
    Read the warning, when it applies and the studies cited

    N-ACETYL-L-CYSTEINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).

    Sources cited by Health Canada (2)
    • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
    • Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed

    Contraindications

    Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).

    Sources cited by Health Canada (4)
    • Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
    • Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
    • Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
    • Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Forté Pharma

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Rinorub Bronches N-acétylcystéine (Forté Pharma): composition and regulation”, https://compoatlas.com/en/supplements/products/139302-rinorub-bronches-n-acetylcysteine, updated 15 November 2026.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line